Login / Signup

The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.

Carlos J ChaccourPaula Ruiz-CastilloMary-Ann RichardsonGemma MoncunillAina CasellasFrancisco Carmona-TorreMiriam GiráldezJuana Schwartz MotaJosé Ramón YusteJosé Ramón AzanzaMiriam FernándezGabriel ReinaCarlota DobañoJoe BrewBelen SadabaFelix HammannRegina Rabinovich
Published in: Trials (2020)
EudraCT number: 2020-001474-29, registered April 1st. Clinicaltrials.gov: submitted, pending number FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Keyphrases
  • sars cov
  • randomized controlled trial
  • respiratory syndrome coronavirus
  • coronavirus disease
  • study protocol
  • early onset
  • clinical trial
  • phase iii
  • sleep quality
  • risk assessment
  • climate change
  • placebo controlled